Results look promising. I am very happy to see that the HbA1c was lowered. I feel more and more confident in Orameds technology and it is only a matter of time before a partner is announced IMO. The Chinese are happy and are full throttle ahead, 2b starting there soon.
Slowly people will realise the bnefits of oral insulin vs injected...
In a way happy that the price is still trading this low from an accumulating point of view!
Glta and happy weekend to all fellow ormp followers
Still alot of question marks surrounding the terapeutical effect. More data from 2b to be released soon including data on HbA1c, which is a bold statement by company ceo...
Partnership with big pharma comng now when technolgy is being more and more de-risked and a more favourable deal can be reached. Also more milestone payments 4+4 musd on the near horizon (one part for completing the technology transfer to the Chinese...)
Exciting times ahead:)
Good article published in market exclusive and nsidermnkey: The top four diabetes best sellers and one oral insulin pill that may threaten them all....
There are a few things to keep in mind when it comes to oral insulin:
1. first pass metabolism is in the liver. So no insulin will be circulating in the bloodflow unchecked. This is a major advantage for oral insulin as it is far safer when the liver gets to regulate. No hypothermia.
2. Orameds product is to be taken at an early starge to delay the onset of diabetes/insulin dependency in type2. Hence it is not intended to replace insulin shots.
3. The longterm effects of oral insulin are unknown, but could prove favourable... If given earlier diabetic neuropathy could be avoided or delayed. Diabetic neuropathy is the biggest cost in diabetes...
4. HbA1c. Time will tell and is critical!
More milestone payments coming soon... Oramed are busy with the technology transfer to our Chinese partners, this is a major milestone...
Fast track would be amazing but doubt that they will get it. There are alternatives and diabetes is not,if treated, life threatening. I am invested in another company who received EAP for their novel and well needed technology to prevent oral mucosit. Very few get this... Glta
vipprimarycare... I am as sure as I can be... I did my due diligence, I suggest you to do yours, that way you will rely on your own understanding based on the info you gather. glta
You are wrong biotech_investor! payment likely be done in about 1,5-2 weeks... Chinese are happy
Robert, good to see you! I can recall that Oramed said they are looking at partnering up after 2b. Could just be talk of course, however I am prepared to take the chance. Like you are saying the technology holds a potential reaching beyond insulin. Maybe this is why Oramed has a colaboration with, a still to be named, big pharma currently testing ormps technology with one of their own products,..?
The Chinese are backed by Sino, a 30++ billion dollar company owned by the state of China, perhaps they do not know what they are doing and are prepared to lose 50musd. From a good source I heard that they are happy with 2b and will continue to pay and honor the agreement.
Looking in the rearview mirror many, if not all, trials and partnerships involving orally/inhaled insulin have failed in one way or another. This ads to the risk....
Looking at present I believe this is the time to make ones decision as we are standing before major potential company events...
My bet is that we will see a partner announced and announcement of achieved milestone (perhaps with full data released on 2b).
Time will tell
Anytime gazzad :)
I believe potential partners/investors are now at the table reviewing data and looking at partnership/investment. The big names are not here but I know a couple of heavy weight individuals that are...
At the end of the day this is a rookie swinging for the parking lot... It is all or nothing. My risk is proportionate to my portfolio and derisked from lucky move when we ran to 30!
In Kidrons We Trust
My guess is that there is WAY too much risk and volatility for institutional investors liking. The majority of the float is held by retail investors and clever traders.
I am waiting on the following news within 0-6 months:
Announcement of partner for phase 3.
Announcement of name/partnership with big pharma currently testing Ormps technology.
Announcement of result for 0901 (glp 1)
Announcement of received milestone pmt from Chinese partner.
Institutional investors will wait to see where this is going and once they feel sure, pay a premium, and step in.
My concern was initially the low 6,5% difference between cohort and placebo. But after calling around and digging, and digging, I now feel confident that Oramed can adjust the dose and deliver a better overall efficiacy profile in ph 3. The key is HbA1c which Oramed must be able to lower in phase 3.
How come Emispheres value is half to Orameds? Emisphere have partnership with Nvo who are launching phase 3... Management of Emisphere is a dubios person. Other partner of Nvo, Merrion, could not afford their operations and sold their IP to Nvo for 3musd plus a potential 10musd in milestone. Not alot for a blockbuster potential med....
Emisphere did not show an improved glucose control in trials when combined with metformin. The glucose was the same without their technology...
I love Nvo it is a great company so think they are on to something... But emsphere would be better of in other management/ownerships hands...
Sanofi did a big mistake partnering up with Mannkind for Afrezza.... Partnership lasted one year during which the sales were pathetic.
The deal between Oramed and Hefei is still on and Hefei will continue to pay. The initial data showing a 6,5% difference between placebo and dosed cohort is signifcant bcause it shows that the technology works. Oramed will address the doses and make sure they will get the redults they are after in 3b...
Until we get news Oramed will go down!
ddocpembroke... I am not sure I follow you here... He paid 8,57 per share... That seems pretty much in line with the share price. Dont think it was an option exercise or similar...
"Leonard Sank, a director of ORAMED PHARMACEUTICALS INC., recently acquired 3,000 shares of the company. The buys took place at $8.57 per share, on May 20, 2016"
Wait and see. In the meantime keep at it biotech investor so I can buy more for cheap!
You said it biotech investor: "Time will tell who was right here."
More data coming soon plus partnership/finance for phase 3. I would be very nervous if I was sitting with a short position in Oramed. The data released so far is very thin, it does not say what the reduction was on average per pill/patient. It just says that on average between cohort and placebo (180 patients) the reduction vas 6.5% which is statistically significant in showing that the technology works. Remember that first pass hepatic metabolism is groundbreaking in diabetes treatment and will be an added bonus to oral insulin.
Once again: Chinese are happy and deal is on. Partnership/finance is being negotiated with big pharma and big banks. Big pharma is testing Orameds technology. Much more to come...
You are wrong biotech investor. I know Chinese are happy with results and are moving forward with agreement. Also several big pharma as well as big banks have approached Oramed since announcement. Glta
Wrong biotech investor, insulin cost is around a dollar and dropping by having access to htit's insulin manufacturing facilities. Remember that oramed 0801 is to be given at an early stage in combination with other medicines to delay the onset of insulin dependency.
The success of Phase IIb means the company will receive the second portion of the investment from Chinese company! partly owned by Sinopharm, which has committed to investing up to $50 million in Oramed based on the achievement of certain conditions.